SUMOylation of the ubiquitin ligase IDOL decreases LDL receptor levels and is reversed by SENP1
Ju-Qiong Wang, Zi-Cun Lin, Liang-Liang Li, Shao-Fang Zhang, Wei-Hui Li, Wei Liu, Bao-Liang Song, Jie Luo
Journal:JOURNAL OF BIOLOGICAL CHEMISTRY
IF:4.24
DOI:10.1074/jbc.RA120.015420
PMID:33154164
Published:2020-11-23
research field:分子生物学细胞生物学心血管研究
Abstract
Inducible degrader of the low-density lipoprotein receptor (IDOL) is an E3 ubiquitin ligase mediating degradation of low-density lipoprotein (LDL) receptor (LDLR). IDOL also controls its own stability through autoubiquitination, primarily at lysine 293. Whether IDOL may undergo other forms of posttranslational modification is unknown. In this study, we show that IDOL can be modified by small ubiquitin-like modifier 1 at the K293 residue at least. The SUMOylation of IDOL counteracts its ubiquitination and augments IDOL protein levels. SUMOylation and the associated increase of IDOL protein are effectively reversed by SUMO-specific peptidase 1 (SENP1) in an activity-dependent manner. We further demonstrate that SENP1 affects LDLR protein levels by modulating IDOL. Overexpression of SENP1 increases LDLR protein levels and enhances LDL uptake in cultured cells. On the contrary, loss of SENP1 lowers LDLR levels in an IDOL-dependent manner and reduces LDL endocytosis. Collectively, our results reveal SUMOylation as a new regulatory posttranslational modification of IDOL and suggest that SENP1 positively regulates the LDLR pathway via deSUMOylation of IDOL and may therefore be exploited for the treatment of cardiovascular disease.
本文使用的Yeasen产品


